Avaleht › Äge müeloidne leukeemia › Michigan
Äge müeloidne leukeemia kliinilised uuringud osariigis Michigan
24 uuringut haiguse Äge müeloidne leukeemia jaoks otsivad osalejaid osariigis Michigan.
Linnad osariigis Michigan
- Ann Arbor17 uuringut
- Detroit14 uuringut
- Grand Rapids7 uuringut
- Livonia7 uuringut
- Canton7 uuringut
- Waterford7 uuringut
- Flint6 uuringut
- Kalamazoo5 uuringut
- Farmington Hills4 uuringut
- Jackson3 uuringut
- Clinton Township3 uuringut
- Warren3 uuringut
Ametlik uuringutekst (inglise keeles)
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ja veel 3
VärbamineFaas 2
Vanused 60 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- ja veel 68
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 40–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ja veel 6
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 28. sept 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Henry Ford Health System, Detroit
- Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- ja veel 14
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- C S Mott Children's Hospital, Ann Arbor
VärbamineFaas 1
Kuni 21 aastane · Kõik sood · Uuendatud 23. sept 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ja veel 6
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
- ja veel 11
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
- ja veel 9
VärbamineFaas 2
Vanused 18–59 · Kõik sood · Uuendatud 22. sept 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- ja veel 1
VärbamineFaas 3
6 Months – 21 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT04293562A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- START Midwest, Grand Rapids
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 11. sept 2026 · NCT06969430Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
VärbamineFaas 3
Vanused 1–25 · Kõik sood · Uuendatud 4. sept 2026 · NCT07022678The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- ja veel 2
VärbamineFaas 1/2
Kuni 22 aastane · Kõik sood · Uuendatud 25. aug 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- C.S. Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
VärbamineFaas 3
29 Days – 21 Years · Kõik sood · Uuendatud 24. aug 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Michigan, Ann Arbor
- Wayne State University School of Medicine, Detroit
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 20. aug 2026 · NCT06001788A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- START Midwest, Grand Rapids
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 7. aug 2026 · NCT07751991Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Henry Ford Cancer Institute, Detroit
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 17. juuli 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Michigan, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
- ja veel 2
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 6. juuli 2026 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- University of Michigan, Ann Arbor
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 15. juuni 2026 · NCT05768932Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- West Michigan Cancer Center, Kalamazoo
VärbamineVaatlusuuring
Vanused 18 ja vanemad · Kõik sood · Uuendatud 7. mai 2026 · NCT02269592A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Karmanos Cancer Institute, Detroit
VärbamineFaas 2
Vanused 18–66 · Kõik sood · Uuendatud 17. märts 2026 · NCT06859424A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Michigan Comprehensive Cancer Center, Ann Arbor
- Karmanos Cancer Institute, Detroit
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 13. märts 2026 · NCT05735184HPC Offered for PRESERVE Expansion
- Henry Ford Health, Detroit
VärbamineVaatlusuuring
Vanused 12–80 · Kõik sood · Uuendatud 28. aug 2025 · NCT07145411Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.